{
  "schemaVersion": 1,
  "contentDigest": "95e7ed2c7957ce60992326f170f37b9c50cd482b4d588594d48aae90d3f3700a",
  "id": "news-oct22-a2-abu-dhabi-ai-cancer-drug-discovery-partnership-2026-10-20",
  "language": "en",
  "interfaceLanguage": "en",
  "url": "https://voltformer.com/news/burjeel-avatrial-explore-ai-cancer-drug-discovery-abu-dhabi",
  "slug": "burjeel-avatrial-explore-ai-cancer-drug-discovery-abu-dhabi",
  "category": "policy-standards",
  "publishDate": "2026-10-20",
  "sourceName": "Emirates News Agency (WAM)",
  "sourceUrl": "https://www.wam.ae/en/article/c2u6plc-burjeel-avatrial-partner-develop-first-of-its-kind",
  "readingTimeMinutes": 1,
  "tags": [
    "United Arab Emirates",
    "Artificial intelligence",
    "Biotechnology",
    "Pharmaceuticals"
  ],
  "content": {
    "title": "Burjeel and Avatrial explore AI cancer-drug research in Abu Dhabi",
    "summary": "Their MoU is exploratory and names no committed investment or launch date.",
    "sections": [
      {
        "paragraphs": [
          "Burjeel Holdings and UK biotech firm Avatrial signed an MoU to explore an AI-enabled cancer-drug discovery ecosystem in Abu Dhabi. The proposed collaboration would combine Burjeel’s regional clinical expertise with Avatrial’s research; no committed investment or launch date was announced."
        ],
        "sources": [
          {
            "name": "Emirates News Agency (WAM)",
            "url": "https://www.wam.ae/en/article/c2u6plc-burjeel-avatrial-partner-develop-first-of-its-kind"
          }
        ]
      }
    ]
  },
  "companies": [],
  "sourceVersion": "0147d129513508ce93f1238a1f285516ce5acefb8efa08f63ba687be9e10630d"
}